Table 2.
Laboratory parameters at baseline and 3 mo later
| Baseline | 3 mo | Percentage change | |
| Fasting plasma glucose, mg/dL (mmol/L) | |||
| Switch to the highest dose rosuvastatin | 91 ± 26 (5.1 ± 1.4) | 95 ± 19 (5.3 ± 1.1) | 4%b |
| Add-on-statin ER-NA/LRPT | 93 ± 17 (5.2 ± 0.9) | 102 ± 27 (5.7 ± 1.5) | 10%bdf |
| Add-on-statin fenofibrate | 94 ± 10 (5.2 ± 0.6) | 94 ± 11 (5.2 ± 0.6) | 0% |
| HbA1c, % | |||
| Switch to the highest dose rosuvastatin | 6.1 ± 0.5 | 6.3 ± 0.5 | 0.2%b |
| Add-on-statin ER-NA/LRPT | 6.3 ± 1.1 | 6.6 ± 1.2 | 0.3%bdf |
| Add-on-statin fenofibrate | 6.1 ± 0.8 | 6.2 ± 1.0 | 0.10% |
| HOMA-IR index | |||
| Switch to the highest dose rosuvastatin | 1.4 (1.2-2.1) | 1.6 (1.5-2.6) | 14%bf |
| Add-on-statin ER-NA/LRPT | 1.5 (1.4-2.1) | 2.5 (1.5-2.8) | 65%bdf |
| Add-on-statin fenofibrate | 1.7 (1.5-2.3) | 1.6 (1.4-2.2) | -6%b |
Values are expressed as mean ± SD [except for fasting plasma insulin and HOMA-IR index which are expressed as median (range)]. No significant differences in baseline data were found across groups.
b
P < 0.01 vs baseline;
d
P < 0.01 vs switch to the highest dose rosuvastatin group;
f
P < 0.01 vs add-on-statin fenofibrate group. ER-NA/LRPT: Extended release nicotinic acid/laropiprant; HOMA-IR index: Homeostasis model assessment of insulin resistance index; HbA1c: Glycosylated haemoglobin.